# Study of ASTX029 in Subjects With Advanced Solid Tumors

> **NCT03520075** · PHASE1,PHASE2 · COMPLETED · sponsor: **Taiho Oncology, Inc.** · enrollment: 192 (actual)

## Conditions studied

- Solid Tumor, Adult

## Interventions

- **DRUG:** ASTX029
- **DRUG:** ASTX029

## Key facts

- **NCT ID:** NCT03520075
- **Lead sponsor:** Taiho Oncology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-07
- **Primary completion:** 2024-08-01
- **Final completion:** 2025-03-03
- **Target enrollment:** 192 (ACTUAL)
- **Last updated:** 2025-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03520075

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03520075, "Study of ASTX029 in Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03520075. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*